Source link : https://www.newshealth.biz/health-news/tildrakizumab-shows-durable-response-in-scalp-psoriasis/
TOPLINE: Tildrakizumab was well tolerated and achieved sustained response in patients with moderate to severe plaque psoriasis of the scalp in a phase 3 study. METHODOLOGY: A 72-week, multicenter, randomized, double-blind, placebo-controlled phase 3b trial enrolled 231 patients with moderate to severe plaque psoriasis of the scalp. Patients were randomly assigned to receive placebo (n […]
Author : News Health
Publish date : 2024-12-30 10:57:06
Copyright for syndicated content belongs to the linked Source.
inHealth